Alkermes
ALKS | NASDAQ
$46.53
-$0.50 (-1.06%)
At close: Nov 16, 2026, 4:00 PM ET
$46.53
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Alkermes Company Profile
Company profile explainedCompany Profile
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Key Executives
| Name | Position |
|---|---|
| Blair C. Jackson | President, CEO & Director |
| David Joseph Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary |
| Joshua Reed | Senior Vice President & Chief Financial Officer |
| Tom Skoff | SVP & Chief Information Officer |
| Christian Todd Nichols | Senior Vice President & Chief Commercial Officer |
| Craig C. Hopkinson | Executive Vice President of Research & Development and Chief Medical Officer |
| Declan O'Connor | Senior Vice President of Operations and Environment, Health & Safety |
| Peter Norman | SVP of Policy, Government & Community Relations |
| Samuel J. Parisi | Interim Principal Accounting Officer & Vice President of Finance |
| Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations |
| Stephen Schiavo | Senior Vice President & Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | 4 | Filing |
| Oct 09, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 18, 2026 | 3 | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 12, 2026 | 8-K | Current Report |
Alkermes
| Country | Ireland |
| IPO Date | Jul 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,050 |
| CEO | Blair Jackson |
Stock Details
| Ticker Symbol | ALKS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001520262 |
| CUSIP Number | G01767105 |
| ISIN Number | IE00B56GVS15 |
| SIC Code | 2834 |
Recent News
- 21 hours ago / marketbeat.comAlkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
- 12 days ago / businesswire.comAlkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
- 13 days ago / seekingalpha.comAlkermes plc (ALKS) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comWhat Alkermes (ALKS) Said on Its Q3 Earnings Call
- 14 days ago / zacks.comAlkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
- 14 days ago / zacks.comAlkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
- 14 days ago / businesswire.comAlkermes plc Reports Third Quarter 2026 Financial Results
- 18 days ago / businesswire.comAlkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
- 18 days ago / seekingalpha.comAlkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
- 27 days ago / businesswire.comAlkermes to Report Third Quarter Financial Results on November 3, 2026
Add to Watchlist
Select watchlists to add or remove ALKS